We speculated that, on the base of inhibition of the BCR-ABL activity, JAK2/STAT5 pathway in pharmacologic interference appeared a promising therapeutic strategy in resistant CML. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.